For more information about these clinical trials please contact the Cardiomyopathy Treatment Program at 319-356-1028, or by mail at University of Iowa Hospitals and Clinics, 200 Hawkins Dr., T416 General Hospital, Iowa City, IA 52242.

• Momentum
• RED-HF
• TOPCAT
• PROTECT
• Pulmonary Hypertension

"A Multi-Center Controlled Trial of the Orqis Medical Cancion- Cardiac Recovery System (CRS) for the Use in Treatment of Acute Decompensated Heart Failure in a Chronic Heart Population Requiring Hospitalization and Intravenous Pharmacologic Intervention."

• This trial compares the safety and additive effectiveness of the Orqis Medical CRS used in conjunction with standard medical therapy for the treatment of acute decompensated heart failure not responding to IV inotrope therapy
• CRS is a minimally invasive system that enables the failing heart to rest via a proprietary cardiac recovery system (CRS) that supplements blood flow to the descending aorta - accessing only peripheral arteries and never directly connecting to the heart
• The primary investigator is Barry Cabuay, MD
• The study coordinator is Page Scovel, RN
• For more information on the Cancion CRS go to www.orqis.com

RED-HF

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia.

• A phase III trial that is studying using Darbepoetin Alfa vs. placebo in heart failure patients with anemia
• Must have a hemoglobin between 9-11 g/dl
• Must have a left ventricular ejection fraction (LVEF) less than or equal to 35 percent
• Study treatment will last approximately 3 years
• The primary investigator is Barry Cabuay, MD
• The study coordinator is Holly Verry, RN

For more information or questions contact Holly Verry, RN.

TOPCAT

A multicenter, randomized, double-blind, placebo-controlled study of the Treatment Of Preserved Cardiac function heart failure with an Aldosterone anTagonist.

• A trial that is studying using spironolactone vs. placebo in diastolic heart failure patients
• Must have a left ventricular ejection fraction (LVEF) of at least 45 percent
• Study treatment will last approximately 4.5 years
• The primary investigator is Barry Cabuay, MD
• The study coordinator is Holly Verry, RN

For more information or questions contact Holly Verry, RN.

PROTECT

A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy.

• Must be hospitalized for heart failure with signs and symptoms of volume overload
• Must require treatment with IV lasix (furosemide)
• Must have impaired kidney function with creatinine clearance between 20-80mL/min
• Up to 3 days of a 4 hours study drug infusion
• Follow-up appointment at 7 day and 14 day after discharge
• The primary investigator is Barry Cabuay, MD
• The study coordinator is Cyndi Larew, RN

For more information or questions contact Cyndi Larew, RN.